$2.51
N/A
Last update: Nov 9, 5:51 PM
Protara Therapeutics Inc
TARANASDAQ
Protara Therapeutics fell 44.6% from $4.53 to $2.51, behind the S&P 500's +10.5%. Its worst day was Feb 24 (−26.4%), and its low came Nov 5 at $2.13.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.31 beat the $-0.40 estimate on $0.00 revenue.
0.0% · S&P 500 +1.6%
Protara Therapeutics closed at its highest level of the year, 66.9% above where the year started.
Story events cover the past 12 months · Times ET
+2.6% · S&P 500 +0.9%
Protara Therapeutics shares fell 18.8%, while the S&P 500 rose 0.2%.
−18.8% · S&P 500 +0.2%
Protara Therapeutics shares rose 11.8%, while the S&P 500 fell 2.0%.
+11.8% · S&P 500 −2.0%
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026Company to host
−26.4%, the year's worst day · S&P 500 +0.7%
EPS of $-0.37 missed the $-0.32 estimate on $0.00 revenue.
−0.7% · S&P 500 −0.2%
EPS of $-0.31 beat the $-0.37 estimate on $0.00 revenue.
+1.0% · S&P 500 +0.6%
EPS of $-0.36 missed the $-0.32 estimate on $0.00 revenue.
−4.9% · S&P 500 −0.3%
EPS of $-0.35 beat the $-0.36 estimate on $0.00 revenue.
+8.0% · S&P 500 +0.3%
Where it ended: a close of $2.51 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 9, 2027 (EPS est. $-0.38).
Nothing in the past 12 months.
All TARA dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TARA and SPY from Benzinga historical bars. Not investment advice.
